<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143077">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02105584</url>
  </required_header>
  <id_info>
    <org_study_id>OCC201202</org_study_id>
    <secondary_id>CIV-13-09-011614</secondary_id>
    <nct_id>NCT02105584</nct_id>
  </id_info>
  <brief_title>Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation</brief_title>
  <acronym>OLAAC</acronym>
  <official_title>Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized, study of the safety and efficacy of the Occlutech®
      LAA occluder indicated for percutaneous LAA closure in  adult male or female patients with
      atrial fibrillation. Safety and efficacy will be assessed at day 1, 30 and 90, and after 1
      year following implantation of an Occlutech® LAA Occluder.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Successful implantation of the Occlutech LAA closure device with less than 7% occurrence of major complications..</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A major complication is defined as an event that results in death, procedure related stroke, systemic embolism, device embolisation, pericardial effusion (cardiac tamponade), or other major bleeding requiring invasive treatment or blood transfusions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>LAA closure device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of LAA closure device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of LAA closure device</intervention_name>
    <arm_group_label>LAA closure device</arm_group_label>
    <other_name>Occlutech LAA occluder in different sizes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented paroxysmal, persistent or chronic non-valvular AF

          -  Calculated CHA2DS2 -VASC score equal or greater than 2 and/or HAS-BLED score equal or
             greater than 2

          -  Patients eligible or non-eligible for lifelong, oral anticoagulation therapy

          -  Life expectancy of at least 1 year

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study

        Exclusion Criteria:

          -  Suspected or known intracardiac thrombus

          -  NYHA Class IV CHF

          -  Patients who has unstable and intractable angina pectoris

          -  ASD and/or atrial septal repair or closure device

          -  Recent myocardial infarction within 3 months

          -  Severe valvular heart disease, or implanted mechanical valve prosthesis

          -  Large PFO with significant atrial septal aneurysm

          -  Planned ablation procedure within 30 days of Occlutech LAA occluder®  implant

          -  Resting heart rate &gt; 110 bpm

          -  Allergy to Nitinol, which is a result of nickel and/or titanium allergies

          -  Stroke/TIA within the last 30 days

          -  Thrombocytopenia, thrombocytosis, leukopenia, or anemia

          -  Symptomatic carotid artery disease

          -  LVEF &lt; 30%

          -  Mitral valve stenosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Brachmann, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Coburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Brachmann, Prof</last_name>
    <email>johannes.brachmann.BB@klinikum-Coburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jai-Wun Park, Prof</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jai-Wun Park, Prof</last_name>
      <email>jai-wun.park@klinikum-coburg.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Brachmann, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jai-Wun Park, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
